Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humana Coverage Policy For Gilenya Promotes Second-Line Use

Executive Summary

Humana’s medical coverage policy for Novartis’ new multiple sclerosis drug Gilenya (fingolimod) requires prior authorization documenting the patient has already tried and failed treatment with other drugs.

You may also be interested in...



Gilenya Could Surpass Avonex Market Share, Analysts Say

Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.

Gilenya Could Surpass Avonex Market Share, Analysts Say

Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.

Novartis' Gilenya: Efficacy, Patient Assistance Lie At Heart Of Marketing Push

As Novartis' multiple sclerosis treatment Gilenya (fingolimod) hits the market, the company is hoping to move beyond the fact that the drug is the first-ever oral drug for general treatment for the disease and highlight its clinical efficacy compared with other MS drugs.

Topics

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel